TXNIP in Metabolic Regulation: Physiological Role and Therapeutic Outlook

• Published in: Current drug targets Vol. 18; no. 9; p. 1095
• Main Authors: Alhawiti, Naif Mohammad, Al Mahri, Saeed, Aziz, Mohammad Azhar, Malik, Shuja Shafi, Mohammad, Sameer
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01.07.2017
• Subjects: Adipogenesis; Carrier Proteins - physiology; Glucose - metabolism; HeLa Cells; Humans; Insulin Resistance; Liver - metabolism; Treatment Outcome; thioredoxin system; metabolic homoeostasis; Diabetes mellitus; pancreatic β-cell dysfunction; thioredoxin-interacting protein; insulin resistance; oxidative stress
• ISSN: 1873-5592
• DOI: 10.2174/1389450118666170130145514

Background & Objective: Thioredoxin-interacting protein (TXNIP) also known as thioredoxin binding protein-2 is a ubiquitously expressed protein that interacts and negatively regulates expression and function of Thioredoxin (TXN). Over the last few years, TXNIP has attracted considerable attention due to its wide-ranging functions impacting several aspects of energy metabolism. TXNIP acts as an important regulator of glucose and lipid metabolism through pleiotropic actions including regulation of β-cell function, hepatic glucose production, peripheral glucose uptake, adipogenesis, and substrate utilization. Overexpression of TXNIP in animal models has been shown to induce apoptosis of pancreatic β-cells, reduce insulin sensitivity in peripheral tissues like skeletal muscle and adipose, and decrease energy expenditure. On the contrary, TXNIP deficient animals are protected from diet induced insulin resistance and type 2 diabetes. Consequently, targeting TXNIP is thought to offer novel therapeutic opportunity and TXNIP inhibitors have the potential to become a powerful therapeutic tool for the treatment of diabetes mellitus. Here we summarize the current state of our understanding of TXNIP biology, highlight its role in metabolic regulation and raise critical questions that could help future research to exploit TXNIP as a therapeutic target.